Model of metastatic growth valuable for radionuclide therapy
Model of metastatic growth valuable for radionuclide therapy
复制标题
DOI：
10.1118/1.1628851
复制
发表时间：
2003-12-01
期刊：
影响因子：
3.8
通讯作者：
Forssell-Aronsson, E
中科院分区：
文献类型：
--
作者：
Bernhardt, P;Ahiman, H;Forssell-Aronsson, E
目的是进行蒙特卡罗模拟方法，以估计肿瘤大小的分布，并研究放射性核素治疗的三种候选放射性核素的治疗潜力：高能电子发射体Y-90，中能电子发射体Lu-177和低能电子发射体Rh-103 m。使用了一名肝细胞癌患者，其最近发表了关于肝脏肿瘤生长的系列CT数据。根据这些数据，估计原发肿瘤的生长和转移形成率。假设原发性和所有转移瘤的肿瘤生长相同，原发性和转移瘤的转移瘤形成率相同，则模拟不同时间点的转移瘤大小分布。针对三种放射性核素的均匀活性分布模拟转移性大小分布的肿瘤治愈;高能电子发射体Y-90、平均能量电子发射体Lu-177和低能电子发射体Rh-103 m。针对不同时间点和肿瘤与正常组织活性浓度TNC进行肿瘤治愈的模拟。结果表明，重要的是在诊断后尽早开始治疗。这对……至关重要。使用最佳放射性核素进行治疗。这些模拟表明，Y-90不适合全身放射性核素治疗，因为小肿瘤（< 1 mg）中发射电子的吸收分数较低。如果TNC低，Rh-103 m略优于Lu-177。对于高TNC值，低能量电子发射体，例如，Rh-103 m是治疗肿瘤的最佳选择。然而，Rh-103 m的短半衰期（56分钟）可能不是治疗的最佳选择。因此，其他低能电子发射体，或α发射体，应考虑全身靶向治疗。(C)2003年美国医学物理学家协会。
The aim was to make a Monte Carlo simulation approach to estimate the distribution of tumor sizes and to study the curative potential of three candidate radionuclides for radionuclide therapy: the high-energy electron emitter Y-90, the medium-energy electron emitter Lu-177 and the low-energy electron emitter Rh-103m. A patient with hepatocellular carcinoma with recently published serial CT data on tumor growth in the liver was used. From these data the growth of the primary tumor, and the metastatis formation rate, were estimated. Assuming the same tumor growth of the primary and all metastases and the same metastatis formation rate from both primary and metastases the metastatic size distribution was simulated for various time points. Tumor cure of the metastatic size distribution was simulated for uniform activity distribution of three radionuclides; the high-energy electron emitter Y-90, the mean-energy electron emitter Lu-177 and the low-energy electron emitter Rh-103m. The simulation of a tumor cure was performed for various time points and tumor-to-normal tissue activity concentrations, TNC. It was demonstrated that it is important to start therapy as early as possible after diagnosis. It was of crucial importance to. use an optimal radionuclide for therapy. These simulations demonstrated that Y-90 was not suitable for systemic radionuclide therapy, due to the low absorbed fraction of the emitted electrons in small tumors (< 1 mg). If TNC was low Rh-103m was slightly better than Lu-177. For high TNC values low-energy electron emitters, e.g., Rh-103m was the best choice for tumor cure. However, the short half-life of Rh-103m (56 min) might not be optimal for therapy. Therefore, other low-energy electron emitters, or alpha emitters, should be considered for systemic targeted therapy. (C) 2003 American Association of Physicists in Medicine.